NEW YORK, Dec.1, 2016
/PRNewswire/ --
Adeptus Health Inc. (ADPT)
Lifshitz & Miller announces investigation on behalf of ADPT
investors concerning whether ADPT adequately disclosed its billing
practices, especially with lower acuity level patients.
If you are an ADPT investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Avid Technology, Inc. (AVID)
Lifshitz & Miller announces investigation on behalf of AVID
investors concerning whether AVID adequately disclosed the launch
of its new NEXIS solution product offerings and third quarter 2016
bookings and revenues.
If you are an AVID investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Cempra, Inc. (CEMP)
Lifshitz & Miller announces investigation on behalf of CEMP
investors concerning whether CEMP adequately disclosed the safety
risks of CEMP's drug solithromycin for hepatotoxicity.
If you are a CEMP investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Clovis Oncology, Inc. (CLVS)
Lifshitz & Miller announces investigation on behalf of CLVS
investors concerning whether CLVS adequately disclosed test data
for rociletinib, CLVS' lung cancer drug.
If you are a CLVS investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Impax Laboratories, Inc. (IPXL)
Lifshitz & Miller announces investigation on behalf of IPXL
investors concerning whether IPXL engaged in a scheme to fix
generic drug prices with other pharmaceutical companies.
If you are a IPXL investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Ligand Pharmaceuticals Incorporated (LGND)
Lifshitz & Miller announces investigation on behalf of LGND
investors concerning whether LGND adequately disclosed certain
deferred tax assets and outstanding convertible senior unsecured
notes.
If you are an LGND investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Pattern Energy Group Inc. (PEGI)
Lifshitz & Miller announces investigation on behalf of PEGI
investors concerning whether PEGI adequately disclosed various
transaction, process level and monitoring controls.
If you are a PEGI investor, and would like additional
information about our investigation, please complete the
Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Kandi Technologies Group, Inc. (KNDI)
Lifshitz & Miller announces
investigation on behalf of KNDI
investors. The investigation concerns whether
KNDI violated federal securities laws by issuing
false and misleading statements concerning KNDI’s
financial results for the third quarter 2016.
If you are a KNDI investor, and
would like additional information about our
investigation, please complete the
Information Request Form or
contact Joshua Lifshitz,
Esq. by telephone at
(516)493-9780
or e-mail at
info@jlclasslaw.com.
ATTORNEY ADVERTISING. © 2016 Lifshitz &
Miller. The law firm responsible for this advertisement is Lifshitz
& Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar
outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz,
Esq.
Lifshitz & Miller
Phone: 516-493-9780
Facsimile:
516-280-7376
Email: info@jlclasslaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-adeptus-health-inc-avid-technology-inc-cempra-inc-clovis-oncology-inc-impax-laboratories-inc-ligand-pharmaceuticals-incorporated-pattern-energy-group-inc-and-ka-300371505.html
SOURCE Lifshitz & Miller Law Firm